Levels of prolactin in relation to coagulation factors and risk of venous thrombosis Results of a large population-based case-control study (MEGA-study)

Autor: Jan W. A. Smit, Victor E. A. Gerdes, Olaf M. Dekkers, Frits R. Rosendaal, Harry R. Büller, Suzanne C. Cannegieter, Bregje van Zaane, Jan Debeij, Danka J. F. Stuijver
Přispěvatelé: Vascular Medicine, Amsterdam Cardiovascular Sciences
Jazyk: angličtina
Rok vydání: 2012
Předmět:
Male
0301 basic medicine
Time Factors
Physiology
030204 cardiovascular system & hematology
0302 clinical medicine
Pregnancy
Recurrence
risk factors
Netherlands
media_common
Cardiovascular diseases [NCEBP 14]
biology
Convalescence
Venous Thromboembolism
Hematology
Middle Aged
Thrombosis
Venous thrombosis
C-Reactive Protein
Female
fibrinolysis
venous thrombosis
Menopause
Adult
Risk
medicine.medical_specialty
prolactin
Hormone Replacement Therapy
media_common.quotation_subject
Contraceptives
Oral
Hormonal

Young Adult
03 medical and health sciences
Von Willebrand factor
Internal medicine
von Willebrand Factor
medicine
Humans
Aged
Factor VIII
Coagulation
business.industry
Pregnancy Complications
Hematologic

Case-control study
Odds ratio
medicine.disease
Confidence interval
Prolactin
Hyperprolactinemia
030104 developmental biology
Endocrinology
Case-Control Studies
biology.protein
business
Zdroj: Thrombosis and Haemostasis, 108(3), 499-507
Thrombosis and Haemostasis, 108, 499-507
Thrombosis and haemostasis, 108(3), 499-507. Schattauer GmbH
Thrombosis and Haemostasis, 108, 3, pp. 499-507
ISSN: 0340-6245
Popis: Contains fulltext : 108512.pdf (Publisher’s version ) (Closed access) The pituitary hormone prolactin is thought to influence coagulation. We aimed to study the relation between prolactin levels, coagulation factors and risk of venous thrombosis (VT). We used data from a large population based case-control study into aetiology of first VT (MEGA-study). Prolactin levels were determined in 2,068 patients with VT and 2,785 age- and sex matched control subjects. The relation between levels of coagulation factors and prolactin was studied among the controls. In addition, odds ratios (OR) and 95% confidence intervals (95%CI) were calculated for the risk of VT for different cut-off points of prolactin levels based on percentiles determined in the controls. Restricted analysis was performed among cases in whom blood was sampled within six months after VT. We found a rise in factor VIII and von Willebrand factor with increasing levels of prolactin in the controls. An increased risk of VT was observed when blood was sampled within six months after thrombosis (OR 2.9, 95%CI 1.1-8.1) for prolactin levels above the 99th percentile (42.6 mug/l) relative to levels between the 20th to 80th percentile. When blood was sampled more than six months after VT no clear association could be observed (OR 1.3, 95%CI 0.7-2.3). In conclusion, we found a modest association between prolactin and symptomatic venous thromboembolism, particularly when blood was sampled close to the event. This may be explained by a causal relation or by prolactin being a marker of stress due to the thrombotic event.
Databáze: OpenAIRE